Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research and Treatment
Erschienen in: Breast Cancer Research and Treatment 1/2011

01.05.2011 | Invited Commentary

Biomarkers of PARP inhibitor sensitivity

verfasst von: Nicholas C. Turner, Alan Ashworth

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Excerpt

The PARP inhibitors represent one of the most exciting recent developments in cancer therapy. Substantial efficacy has been shown with PARP inhibitors in the treatment of hereditary BRCA1/2 related Breast and Ovarian cancer as single agents [1‐3] and in combination with temozolomide [4]. Similarly, encouraging activity has been shown in sporadic ovarian cancer with a PARP inhibitor as a single agent [5], and in sporadic triple negative breast cancer in combination with gemcitabine/carboplatin chemotherapy [6]. Yet the picture is not universally positive. Negative studies have been reported in heavily pre-treated sporadic triple negative cancer, with PARP inhibitor as a single agent [5] and no evidence of activity in combination with temozolomide [4]. To understand the reasons some studies have succeeded, and others failed, the development of biomarkers that will predict the sensitivity, or resistance, to PARP inhibitors is required. …
Literatur
1.
Audeh MW et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376(9737):245–251PubMedCrossRef
2.
Tutt A et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235–244PubMedCrossRef
3.
Sandhu SK, Wenham RM, Wilding G, McFadden M, Sun L, Toniatti C, Stroh M, Carpenter CL, De Bono JS, Schelman WR (2010) First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers. J Clin Oncol 28(15s): p Abstract 3001
4.
Isakoff SJ, Overmoyer B, Tung NM, Gelman RS, Giranda VL, Bernhard KM, Habin KR, Ellisen LW, Winer EP, Goss PE (2010) A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 28(15s): p Abstract 1019
5.
Gelmon KA, Hirte HW, Robidoux A, Tonkin KS, Tischkowitz M, Swenerton K, Huntsman D, Carmichael J, Macpherson E, Oza AM (2010) Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. J Clin Oncol 28(15s): p Abstract 3002
6.
O’Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, Rocha C, Ossovskaya V, Sherman B, Bradley C (2009) Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 27(18s): p Abstract 3
7.
McCabe N et al (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66(16):8109–8115PubMedCrossRef
8.
Farmer H et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917–921PubMedCrossRef
9.
Esteller M et al (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92(7):564–569PubMedCrossRef
10.
Yu PJ et al (2007) Basic fibroblast growth factor (FGF-2): the high molecular weight forms come of age. J Cell Biochem 100(5):1100–1108PubMedCrossRef
11.
Mendes-Pereira AM et al (2009) Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1(6–7):315–322PubMedCrossRef
12.
Schaffner C et al (1999) Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 94(2):748–753PubMed
13.
Stilgenbauer S et al (1997) Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med 3(10):1155–1159PubMedCrossRef
14.
Wen Q et al (2008) A mutant allele of MRE11 found in mismatch repair-deficient tumor cells suppresses the cellular response to DNA replication fork stress in a dominant negative manner. Mol Biol Cell 19(4):1693–1705PubMedCrossRef
15.
Olopade OI, Wei M (2003) FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 3(5):417–420PubMedCrossRef
16.
Turner N, Tutt A, Ashworth A (2004) Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4(10):814–819PubMedCrossRef
17.
Brustmann H (2007) Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome. Int J Gynecol Pathol 26(2):147–153PubMed
18.
Bartkova J et al (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444(7119):633–637PubMedCrossRef
19.
Weigelt B et al (2010) Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 11(4):339–349PubMedCrossRef
20.
von Minckwitz G, Müller B, Loibl S, Blohmer JU, duBois A, Huober J, Kandolf R, Budcizes J, Denkert C (2010) PARP is expressed in all subtypes of early breast cancer and is a predictive factor for response to neoadjuvant chemotherapy. Eur J Cancer Suppl 8:188
21.
Loibl S, Müller B, Von Minckwitz G, Blohmer JU, Bois Ad, Huober JB, Fend F, Budczies J, Denkert C (2010) PARP expression in early breast cancer and its predictive value for response to neoadjuvant chemotherapy. J Clin Oncol 28(15s): p Abstract 10511
22.
Gottipati P et al (2010) Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 70(13):5389–5398PubMedCrossRef
23.
Zaremba T et al (2009) Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines. Br J Cancer 101(2):256–262PubMedCrossRef
24.
Yang SX et al (2009) Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biol Ther 8(21):2004–2009PubMedCrossRef
25.
Konstantinopoulos PA et al (2010) Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 28(22):3555–3561PubMedCrossRef
26.
Rodriguez AA et al (2010) DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat 123(1):189–196PubMedCrossRef
27.
Holstege H et al (2009) High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res 69(8):3625–3633PubMedCrossRef
28.
Silver DP et al (2010) Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28(7):1145–1153PubMedCrossRef
29.
Godon C et al (2008) PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility. Nucleic Acids Res 36(13):4454–4464PubMedCrossRef
30.
Bryant HE et al (2009) PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J 28(17):2601–2615PubMedCrossRef
31.
Swisher EM et al (2008) Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 68(8):2581–2586PubMedCrossRef
32.
Edwards SL et al (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451(7182):1111–1115PubMedCrossRef
33.
Fong PC et al (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28(15):2512–2519PubMedCrossRef
34.
Bouwman P et al (2010) 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 17(6):688–695PubMedCrossRef
35.
Bunting SF et al (2010) 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141(2):243–254PubMedCrossRef
36.
Schild D, Wiese C (2010) Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability. Nucleic Acids Res 38(4):1061–1070PubMedCrossRef
37.
Gonçalves A, Finetti P, Sabatier R, Gilabert M, Adelaide J, Borg J-P, Chaffanet M, Viens P, Birnbaum D, Bertucci F (2010) Poly(ADP- ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat. doi: 10.​1007/​s10549-010-1199-y PubMed
Metadaten
Titel
Biomarkers of PARP inhibitor sensitivity
verfasst von
Nicholas C. Turner
Alan Ashworth
Publikationsdatum
01.05.2011
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1375-8

Weitere Artikel der Ausgabe 1/2011

Breast Cancer Research and Treatment 1/2011 Zur Ausgabe

Clinical trial

Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer

Brief Report

Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers

Review

Radiotherapy and breast reconstruction: a meta-analysis

Clinical trial

The effect of various vitamin D supplementation regimens in breast cancer patients

Invited Commentary

Dead-box or black-box: is DDX1 a potential biomarker in breast cancer?

Epidemiology

No association of polymorphisms in the cell polarity gene SCRIB with breast cancer risk

Neu im Fachgebiet Onkologie

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise